[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100599090":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":35,"locations":41,"responsibleParty":65,"collaborators":34,"id":67,"slug":68,"hasResults":69,"nctId":70,"briefTitle":71,"officialTitle":72,"acronym":73,"eligibilityCriteria":74,"healthyVolunteers":69,"sex":75,"minAge":76,"maxAge":77,"enrollmentInfo":78,"targetDuration":34,"studyType":81,"phases":82,"briefSummary":84,"conditions":85,"keywords":34,"overallStatus":87,"whyStopped":34,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":92,"completionDateStruct":94,"leadSponsor":96,"locationsCount":97},{"fullName":5,"class":6},"University of Florida","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Active PBM","ACTIVE_COMPARATOR","Participants will receive active photobiomodulation (PBM) delivered to peri-articular knee sites, lumbar segments L2-L5, genicular\u002Fsaphenous nerve fields, and lymphatic drainage zones using the THOR® LX2.3 device and study-specified treatment parameters. Treatment will be administered in six sessions over 2-3 weeks at a frequency of 2-3 sessions per week.",[13],"Device: Photobiomodulation therapy (PBM) device",{"label":15,"type":16,"description":17,"interventionNames":18},"Sham PBM","SHAM_COMPARATOR","Participants will receive sham photobiomodulation (PBM) delivered using a visually identical THOR® LX2.3 device that does not emit therapeutic light. Sham treatment will be administered to the same anatomical sites and according to the same treatment schedule as the active PBM group, consisting of six sessions over 2-3 weeks at a frequency of 2-3 sessions per week.",[19],"Device: Sham PBM device",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DEVICE","Photobiomodulation therapy (PBM) device","FDA-cleared near-infrared PBM device delivering therapeutic light to the affected knee. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks (2-3 times per week).",[9],[27],"light therapy",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Sham PBM device","Identical in appearance to the active PBM device but emits no therapeutic light. Administered once per session, approximately 10 minutes after topical application, in six sessions over 2-3 weeks.",[15],[33],"placebo light therapy",null,[36],{"name":37,"role":38,"phone":39,"phoneExt":34,"email":40},"Selenia Rubio, MD. MBA,","CONTACT","352-273-5590","srubio7@ufl.edu",[42],{"facility":5,"status":34,"city":43,"state":44,"zip":45,"country":46,"countryCode":47,"cosmosGeoPoint":48,"geoPoint":53,"contacts":54},"Gainesville","Florida","32610","United States","US",{"type":49,"coordinates":50},"Point",[51,52],-82.32483,29.65163,{"lat":52,"lon":51},[55,57,60,63],{"name":56,"role":38,"phone":39,"phoneExt":34,"email":40},"Selenia Rubio, MD., MBA",{"name":58,"role":59,"phone":34,"phoneExt":34,"email":34},"Margarete C Ribeiro-Dasilva","PRINCIPAL_INVESTIGATOR",{"name":61,"role":62,"phone":34,"phoneExt":34,"email":34},"Roger B Fillingim, PhD","SUB_INVESTIGATOR",{"name":64,"role":62,"phone":34,"phoneExt":34,"email":34},"Roland Staud, MD, FACP",{"type":66,"investigatorFullName":34,"investigatorTitle":34,"investigatorAffiliation":34,"oldNameTitle":34,"oldOrganization":34},"SPONSOR","100599090","effects-of-photobiomodulation-on-inflammation-and-chronic-pain-in-knee-osteoarthritis-epic-ko-100599090",false,"NCT07079969","Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis (EPIC-KO)","Effects of Photobiomodulation on Inflammation and Chronic Pain in Knee Osteoarthritis","EPIC-KO","Inclusion Criteria:\n\n* Clinically confirmed knee osteoarthritis (OA) based on the American College of Rheumatology (ACR) criteria with symptomatic pain for ≥ 3 months\n* Average knee-pain intensity ≥ 30\u002F100 on both the Daily Symptom Diary (DSD) run-in and CATI\n* Age ≥ 50 years\n* Ability to give informed consent, attend visits, and complete ≥ 4 of 7 DSD entries pre-randomization\n* Capacity to perform all study tasks (Timed Up-and-Go, knee OA assessments, blood draw, questionnaires, etc)\n\nExclusion Criteria:\n\nSystemic and Rheumatic Disease\n\n* Active systemic rheumatic condition (e.g., rheumatoid arthritis, systemic lupus erythematosus)\n* Fibromyalgia with pain outside the knee that is equal to or worse than knee pain\n\nMusculoskeletal History\n\n* Clinically significant surgery on the index knee (e.g., arthroplasty, osteotomy)\n* Knee surgery within the past 6 weeks\n* Intra-articular injection to the index knee within the past 14 days\n\nMedication Use\n\n* Daily opioid therapy\n* Hypersensitivity to PBM\n* Migraine triggered by light\n* Open wounds, skin infections, eczema, burns, or other dermatologic conditions at or near the treatment application site.\n* New prescription or OTC analgesic, non-pharmacologic pain therapy, chemotherapy, or radiation therapy initiated ≤ 30 days before screening\n\nCardiovascular Safety\n\n* Uncontrolled hypertension (SBP \\> 150 mmHg or DBP \\> 95 mmHg)\n* Unstable or activity-limiting cardiovascular or peripheral arterial disease\n\nNeurological and Psychiatric Conditions\n\n* Diagnosed neurological disorder (e.g., Parkinson's disease, multiple sclerosis, epilepsy)\n* History or evidence of stroke or moderate-severe traumatic brain injury\n* Serious psychiatric illness requiring hospitalization within the past 12 months\n* Active suicidal ideation\n* Current substance-use disorder or past hospitalization for substance-use treatment\n\nDermatologic Conditions\n\n* Compromised skin integrity at or near the treatment site (e.g., open wounds, active rash, dermatitis, burns, ulcers, eczema, infection) interfering with topical treatment or PBM\n\nOther Metabolic Conditions\n\n* Uncontrolled diabetes\n* Diabetes-related complications (e.g., peripheral neuropathy, severe nephropathy, chronic ulcers at treatment site)\n\nOther Pain Conditions\n\n* Chronic pain at another body site more severe than knee pain\n\nGeneral Health and Cognition\n\n* Pregnancy or lactation\n* Cognitive impairment that precludes informed consent or task participation","ALL","50 Years","99 Years",{"count":79,"type":80},30,"ESTIMATED","INTERVENTIONAL",[83],"NA","This study aims to determine analgesic and anti-inflammatory effects of dual-wavelength PBM in people with symptomatic knee OA.",[86],"Chronic Knee Pain","NOT_YET_RECRUITING","2026-05-22",{"date":90,"type":91},"2026-05-27","ACTUAL",{"date":93,"type":80},"2026-07",{"date":95,"type":80},"2027-07",{"name":5,"class":6},1]